Portopulmonary hypertension as an indication for combined heart, lung, and liver or lung and liver transplantation: Literature review and case presentation
Nicole E. Scouras, Takashi Matsusaki, Charles D. Boucek, Cynthia Wells, Erik A. Cooper, Raymond M. Planinsic, Erin A. Sullivan, Christian A. Bermudez, Yoshiya Toyoda, Tetsuro Sakai – 28 January 2011 – End‐stage liver disease with severe portopulmonary hypertension (PPHTN), which is refractory to vasodilator therapies, is a contraindication for isolated liver transplantation (LT) because of the high mortality rate.